期刊文献+

Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent 被引量:2

原文传递
导出
摘要 Epstein-Barr virus (EBV) is prevalent throughout the world and is associated with several malignant diseases in humans. Latent membrane protein 2 (LMP2) of EBV plays a crucial role in the pathogenesis of EBV-associated tumors; therefore, LMP2 has been considered to be a potential immunodiagnostic and immunotherapeutic target. A multi-epitope-based antigen is a promising option for therapeutic vaccines and diagnoses of such malignancies. In this study, we systematically screened cytotoxic T lymphocyte (CTL), helper T cell (Th) and B-cell epitopes within EBV-LMP2 using bioinformatics. Based on the screen, two peptides rich in overlapping epitopes of both T cells and B cells were selected to construct a plasmid containing the sequence for a chimeric multi-epitope protein referred to as EBV-LMP2m, which is composed of LMP2aa195-232 and LMP2aa419-436. The EBV-LMP2m protein was expressed in E. coil BL21 (DE3) after prokaryotic codon optimization. Inoculation of the purified chimeric antigen in BALB/c mice induced not only high levels of specific IgG in the serum and secretory IgA in the vaginal mucus but also a specific CTL response. By using purified EBV-LMP2m as an antigen, the presence of specific IgG in the serum specimens of 202 nasopharyngeal carcinoma (NPC) patients was effectively detected with 52.84% sensitivity and 95.40% specificity, which represents an improvement over the traditional detection method based on VCA-IgA (60.53% sensitivity and 76.86% specificity). The above results indicate that EBV-LMP2m may be used not only as a potential target antigen for EBV-associated tumors but also a diagnostic agent for NPC patients. Epstein-Barr virus (EBV) is prevalent throughout the world and is associated with several malignant diseases in humans. Latent membrane protein 2 (LMP2) of EBV plays a crucial role in the pathogenesis of EBV-associated tumors; therefore, LMP2 has been considered to be a potential immunodiagnostic and immunotherapeutic target. A multi-epitope-based antigen is a promising option for therapeutic vaccines and diagnoses of such malignancies. In this study, we systematically screened cytotoxic T lymphocyte (CTL), helper T cell (Th) and B-cell epitopes within EBV-LMP2 using bioinformatics. Based on the screen, two peptides rich in overlapping epitopes of both T cells and B cells were selected to construct a plasmid containing the sequence for a chimeric multi-epitope protein referred to as EBV-LMP2m, which is composed of LMP2aa195-232 and LMP2aa419-436. The EBV-LMP2m protein was expressed in E. coil BL21 (DE3) after prokaryotic codon optimization. Inoculation of the purified chimeric antigen in BALB/c mice induced not only high levels of specific IgG in the serum and secretory IgA in the vaginal mucus but also a specific CTL response. By using purified EBV-LMP2m as an antigen, the presence of specific IgG in the serum specimens of 202 nasopharyngeal carcinoma (NPC) patients was effectively detected with 52.84% sensitivity and 95.40% specificity, which represents an improvement over the traditional detection method based on VCA-IgA (60.53% sensitivity and 76.86% specificity). The above results indicate that EBV-LMP2m may be used not only as a potential target antigen for EBV-associated tumors but also a diagnostic agent for NPC patients.
出处 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2016年第4期492-501,共10页 中国免疫学杂志(英文版)
基金 This work was supported by a grant from the National Natural Science Foundation of China (No: 81372447).
关键词 Epstein-Barr virus (EBV) EPITOPE latent membrane protein 2 (LMP2) VACCINE Epstein-Barr virus (EBV) epitope latent membrane protein 2 (LMP2) vaccine
  • 相关文献

参考文献4

二级参考文献39

  • 1http ://hlaligand.ouhsc.edu/LigandDB/servlet/GenerateFormServlet ? form_type=index (2006-12-11)
  • 2http ://www.cbbrowne.com/info/rdbms.html (2006-12-11 )
  • 3http ://hiv-web.lanl.gov/content/hiv-db/LOCATE/locate.html (2006-12- 11)
  • 4http ://ec.europa.eu/research/biot1.html (2006-12-11 )
  • 5DeLisi C, Berzofsky JA. T-cell antigenic sites tend to be amphipathic structures[J]. Proc Natl Acad Sci, 1985, 82(20): 70d8- 7052.
  • 6Rothbard JB, Taylor WR. A sequence pattern common to T cell epitopes[J]. EMBO J, 1988, 7(1): 93-100.
  • 7Sette A, Buus S, Appella E, et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis[J]. Proc Natl Acad Sci, 1989, 86(9): 3296- 3300.
  • 8Hammer J, Belunis C, Bolin D, et al. High affinity binding of short peptides to MHC class Ⅱ molecules by anchor combinations [J]. Proc Natl Acad Sci, 1994, 91(10): 4456-4460.
  • 9Manici S, Sturniolo T, Imro MA, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11 [J]. Exp Med, 1999, 189(5) : 871-876.
  • 10Davenport MP, Ho Shon IA, Hill AV. An empirical method for the prediction of T-cell epitopes[J]. Immunogenetics, 1995, 42 (5): 392-397.

共引文献61

同被引文献8

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部